tiprankstipranks
Australian Clinical Labs Ltd (AU:ACL)
ASX:ACL
Australian Market
ACL
Australian Clinical Labs Ltd
RESEARCH TOOLSreports
Want to see AU:ACL full AI Analyst Report?

Australian Clinical Labs Ltd (ACL) Share Forecast & Price Target

79 Followers
See the Price Targets and Ratings of:

ACL Analyst Ratings

Currently, no data available
Based on NaN analysts giving stock ratings to
Australian
Clinical Labs Ltd
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ACL Stock 12 Month Forecast

There Are No Analyst Ratings for AU:ACL In The Last 3 Months.
Highest Price Target―Average Price Target―Lowest Price Target―
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

ACL Financial Forecast

ACL Earnings Forecast

Next quarter’s earnings estimate for ACL is AU$0.10 with a range of AU$0.10 to AU$0.10. The previous quarter’s EPS was AU$0.07. ACL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ACL has Performed in-line its overall industry.
Next quarter’s earnings estimate for ACL is AU$0.10 with a range of AU$0.10 to AU$0.10. The previous quarter’s EPS was AU$0.07. ACL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ACL has Performed in-line its overall industry.

ACL Sales Forecast

Next quarter’s sales forecast for ACL is AU$374.20M with a range of AU$374.20M to AU$374.20M. The previous quarter’s sales results were AU$361.42M. ACL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ACL has Performed in-line its overall industry.
Next quarter’s sales forecast for ACL is AU$374.20M with a range of AU$374.20M to AU$374.20M. The previous quarter’s sales results were AU$361.42M. ACL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ACL has Performed in-line its overall industry.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Ord Minnett Analyst forecast on AU:ACL
Tom Godfrey
Ord Minnett
Ord Minnett
AU$2.4→AU$2.2
Hold
5.26%
Upside
Reiterated
03/24/26
Ord Minnett Remains a Hold on Australian Clinical Labs Ltd (ACL)
Canaccord Genuity Analyst forecast on AU:ACL
Shane Storey
Canaccord Genuity
Canaccord Genuity
AU$3.85→AU$2.4
Hold
14.83%
Upside
Downgraded
02/17/26
Canaccord Genuity downgrades Australian Clinical Labs Ltd (ACL) to a Hold
Macquarie Analyst forecast on AU:ACL
Unknown Analyst
Macquarie
Not Ranked
Macquarie
AU$2.9→AU$2.3
Hold
10.05%
Upside
Reiterated
02/16/26
Macquarie Reaffirms Their Hold Rating on Australian Clinical Labs Ltd (ACL)
RBC Capital Analyst forecast on AU:ACL
Craig Wong-Pan
RBC Capital
RBC Capital
AU$2.8→AU$2.4
Hold
14.83%
Upside
Reiterated
02/16/26
RBC Capital Reaffirms Their Hold Rating on Australian Clinical Labs Ltd (ACL)
Wilsons Analyst forecast on AU:ACL
Rita Fung
Wilsons
Wilsons
AU$3.85
Buy
84.21%
Upside
Reiterated
08/27/25
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Ord Minnett Analyst forecast on AU:ACL
Tom Godfrey
Ord Minnett
Ord Minnett
AU$2.4→AU$2.2
Hold
5.26%
Upside
Reiterated
03/24/26
Ord Minnett Remains a Hold on Australian Clinical Labs Ltd (ACL)
Canaccord Genuity Analyst forecast on AU:ACL
Shane Storey
Canaccord Genuity
Canaccord Genuity
AU$3.85→AU$2.4
Hold
14.83%
Upside
Downgraded
02/17/26
Canaccord Genuity downgrades Australian Clinical Labs Ltd (ACL) to a Hold
Macquarie Analyst forecast on AU:ACL
Unknown Analyst
Macquarie
Not Ranked
Macquarie
AU$2.9→AU$2.3
Hold
10.05%
Upside
Reiterated
02/16/26
Macquarie Reaffirms Their Hold Rating on Australian Clinical Labs Ltd (ACL)
RBC Capital Analyst forecast on AU:ACL
Craig Wong-Pan
RBC Capital
RBC Capital
AU$2.8→AU$2.4
Hold
14.83%
Upside
Reiterated
02/16/26
RBC Capital Reaffirms Their Hold Rating on Australian Clinical Labs Ltd (ACL)
Wilsons Analyst forecast on AU:ACL
Rita Fung
Wilsons
Wilsons
AU$3.85
Buy
84.21%
Upside
Reiterated
08/27/25
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Australian Clinical Labs Ltd

3 Months
Rita FungWilsons
Success Rate
1/1 ratings generated profit
100%
Average Return
+8.90%
Copying Rita Fung's trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +8.90% per trade.
1 Year
Rita FungWilsons
Success Rate
0/1 ratings generated profit
0%
Average Return
-12.30%
Copying Rita Fung's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -12.30% per trade.
2 Years
Rita FungWilsons
Success Rate
0/1 ratings generated profit
0%
Average Return
-12.30%
Copying Rita Fung's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -12.30% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ACL Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
0
0
0
0
Buy
0
0
0
0
0
Hold
8
8
6
1
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
8
8
6
1
0
In the current month, ACL has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ACL average Analyst price target in the past 3 months is ―.
Each month's total comprises the sum of three months' worth of ratings.

ACL Stock Forecast FAQ

What is AU:ACL’s average 12-month price target, according to analysts?
Currently, no data Available
What is AU:ACL’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for AU:ACL, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is Australian Clinical Labs Ltd a Buy, Sell or Hold?
      Currently, no data Available
      What is Australian Clinical Labs Ltd’s share price target?
      Currently, no data Available
      What do analysts say about Australian Clinical Labs Ltd?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of Australian Clinical Labs Ltd?
      To buy shares of AU:ACL, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.